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ndorepellin, the COOH-terminal domain of the heparan
sulfate proteoglycan perlecan, inhibits several aspects
of angiogenesis. We provide evidence for a novel
biological axis that links a soluble fragment of perlecan
protein core to the major cell surface receptor for collagen I,
 
 
 
2
 
 
 
1 integrin, and provide an initial investigation of the
intracellular signaling events that lead to endorepellin anti-
angiogenic activity. The interaction between endorepellin
and 
 
 
 
2
 
 
 
1 integrin triggers a unique signaling pathway that
causes an increase in the second messenger cAMP; activation
of two proximal kinases, protein kinase A and focal adhesion
E
 
kinase; transient activation of p38 mitogen-activated protein
kinase and heat shock protein 27, followed by a rapid
down-regulation of the latter two proteins; and ultimately
disassembly of actin stress ﬁbers and focal adhesions. The
end result is a profound block of endothelial cell migration
and angiogenesis. Because perlecan is present in both
endothelial and smooth muscle cell basement membranes,
proteolytic activity during the initial stages of angiogenesis
could liberate antiangiogenic fragments from blood vessels’
walls, including endorepellin.
 
Introduction
 
Angiogenesis, the process of new blood vessel formation
from existing blood vessels, allows tumors to expand beyond
a few millimeters by providing oxygen, nutrients, and
waste disposal at distances greater than allowed by diffusion
(Folkman, 2002). Therefore, several antiangiogenic com-
pounds have been characterized as potential cancer therapies.
The mechanisms of action of these compounds are gradually
being elucidated. Increasingly, these studies have demon-
strated the importance of integrins in angiogenesis. For
example, endostatin, a COOH-terminal fragment of collagen
XVIII, interacts with 
 
 
 
5
 
 
 
1 integrin, a major fibronectin
receptor in endothelial cells (Rehn et al., 2001), and causes
disruption of focal adhesions and actin stress fibers by
down-regulating RhoA (Wickström et al., 2002, 2003).
Tumstatin, a portion of collagen IV, binds to 
 
 
 
v
 
 
 
3 inte-
grin and triggers a signaling cascade that leads to inhibition
of endothelial protein synthesis and proliferation (Sudhakar et
al., 2003).
Perlecan, a heparan sulfate proteoglycan expressed in all
vascular basement membranes (Iozzo, 1998), plays a signifi-
cant role in vasculogenesis and tumor angiogenesis (Iozzo
and San Antonio, 2001). Lack of perlecan in mice causes
intra-pericardial hemorrhage and death at embryonic day
10.5 when vasculogenesis is prominent (Arikawa-Hirasawa
et al., 1999; Costell et al., 1999), as well as a high incidence
of cardiac outflow tract malformations and transposition of
great vessels (Costell et al., 2002). Perlecan is secreted by
adult endothelial cells and plays an essential role in regulating
the vascular response to injury in vivo (Nugent et al., 2000).
We recently discovered that the COOH-terminal domain
V of perlecan inhibits several aspects of angiogenesis, includ-
ing endothelial cell migration, collagen-induced capillary
morphogenesis, and blood vessel growth in the chorioallantoic
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membrane and in Matrigel plug assays (Mongiat et al.,
2003). We named it endorepellin (ER) to signify its anti-
endothelial activity. In this work, we investigated the molec-
ular mechanism by which ER alters endothelial cell function.
We found that ER, and one of its laminin G–like (LG) com-
ponents, LG3, in a calcium-dependent but heparan sulfate–
independent fashion, disrupted actin stress fibers and focal
adhesions via interaction with the collagen receptor 
 
 
 
2
 
 
 
1
integrin. This interaction led to a rapid rise in intracellular
cAMP ([cAMP]
 
i
 
) levels, concurrent activation of cAMP-
dependent protein kinase A (PKA), sustained activation of
FAK, and transient activation of p38 MAPK and heat shock
protein 27 (Hsp27), which ultimately culminated into disas-
sembly of actin stress fibers and focal adhesions.
 
Results
 
Recombinant ER and its COOH-terminal LG3 module 
disrupt capillary morphogenesis in Matrigel or 
collagen overlay assays
 
Using 293-EBNA embryonic kidney cells, we generated ER
and two deletion fragments encompassing the two LG mod-
ules and the EGF repeats (LG1/LG2) and the terminal LG3
module (Fig. 1 A). Polyclonal antibodies against ER showed
specific labeling of blood vessels in normal (Fig. 1 B) and
neoplastic tissues (Fig. 1, C and D).
Next, we investigated the antiangiogenic properties of ER
and its fragments using a coculture system within Matrigel.
To this end, we cultured for 24 h wild-type 293-EBNA
cells or clones expressing ER and its fragments within a
three-dimensional Matrigel environment. After 24 h, hu-
man umbilical vein endothelial cells (HUVECs; 
 
 
 
10
 
4
 
)
were seeded on the top and cocultured for another 24 h.
Thus, the HUVECs did not have direct physical contact
with the 293-EBNA cells, which are embedded in the
Matrigel, and any effects on tube formation would be due
to secreted factors. The presence of LG3- (Fig. 1 F) and
ER-secreting (Fig. 1 G) 293-EBNA cells prevented the for-
mation of capillary morphogenesis obtained when HU-
VECs were cultured with either wild-type cells (Fig. 1 E) or
alone (not depicted). No effects were obtained with LG1/
LG2 secreting cells (unpublished data). The conditioned
media were analyzed by Western immunoblotting and
showed the presence of LG3 and ER (Fig. 1, I and J, respec-
tively), in addition to two cross-reacting bands present in
the control samples (Fig. 1 H, asterisks). In further experi-
ments, we found that the two cross-reacting bands were due
to serum proteins because they were not detected when cells
were cultured in serum-free media. To further corroborate
the specificity of these effects, we tested recombinant ER
and its fragments (50–150 nM each for 24 h) on capillary
morphogenesis on Matrigel. The results showed abrogation
of capillary morphogenesis by ER and LG3 but not LG1/
LG2 (Fig. 1, K–N). Similar results were obtained using col-
lagen overlay assays (unpublished data). Thus, these data
suggest that COOH-terminal module LG3 might contain
most of the biological activity of ER.
Figure 1. ER and its COOH-terminal LG3 module disrupt capillary morphogenesis in Matrigel. (A) Purification of ER and two fragments 
encompassing the LG1/LG2 and LG3 domains, respectively, as schematically shown in the right margin. The picture represents a Coomassie-
stained SDS-PAGE of purified recombinant proteins. (B–D) Light micrographs of normal breast (B), breast carcinoma (C), and astrocytoma (D) 
showing specific labeling of blood vessels using the anti-ER antibody. (E–G) Capillary morphogenesis after coculture of 293-EBNA cells 
(within Matrigel) and HUVECs (on top of Matrigel) as indicated. (H–J) Immunoblotting of conditioned media from the corresponding cocultures 
shown in E–G. Notice the presence of LG3 and ER (arrow) in the coculture with the LG3- and ER-secreting 293-EBNA cells. The nonspecific 
bands derived from serum proteins are labeled by asterisks. (K–N) Inhibition of HUVEC capillary morphogenesis on Matrigel by recombinant 
ER and LG3, but not by LG1/LG2 (150 nM, each, for 24 h). Bars, 100  m. 
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Transduction of endothelial cells with
adenovirus-containing ER (Ad-ER) prevents
capillary morphogenesis
 
Next, we determined whether or not the endogenous secre-
tion of ER by endothelial cells via Ad-ER would disrupt cap-
illary morphogenesis in a dominant-negative fashion because
endothelial cells synthesize perlecan (Iozzo, 1998). First, we
determined the effective transduction of several cells with di-
verse histogenetic backgrounds, including HUVECs, hu-
man microvascular dermal endothelial cells (MECs), rat
MTLn3 breast carcinoma cells, and WiDr human colon car-
cinoma cells. These cells showed a significant and dose-
dependent synthesis of ER (Fig. 2 A). Next, we plated HU-
VECs and MECs on fibronectin, collagen I, or laminin for
24 h, and then we transduced them with Ad-ER for 48 h. A
collagen gel was then added to the cells to induce tube for-
mation. Untransduced and HUVECs transduced with con-
trol adenovirus (Fig. 2 B, Ad-Empty) formed tubes (Fig. 2
B), whereas Ad-ER transduced HUVECs failed to do so.
Similar effects were also obtained using recombinant ER or
LG3 (Fig. 2 B), as well as when MECs were used (not de-
picted). Thus, inhibition of capillary morphogenesis is in-
duced by both endogenous synthesis of ER and exogenous
recombinant protein, and these effects occur in endothelial
cells from umbilical vein and dermal microvasculature.
 
ER and LG3, but not LG1/LG2, reversibly disrupt 
endothelial cell actin stress fibers and focal adhesions
 
Next, we investigated if ER and its fragments could interfere
with the cytoskeleton and focal adhesions. HUVECs and
MECs were grown to subconfluency on collagen I and
treated with ER, LG1/LG2, or LG3 for 10 min. Actin stress
fibers and focal adhesions were visualized with rhodamine-
phalloidin or antivinculin antibody, respectively. Both ER
and LG3 caused significant disassembly of actin stress fibers
and focal adhesions, which was fully reversible after 3 h (Fig.
3). In contrast, recombinant LG1/LG2 did not have any ap-
preciable effects (Fig. 3). Quantization of the data showed
a 75–80% (P 
 
  
 
0.001) loss of stress fibers in the ER-
and LG3-treated HUVECs (Fig. S1 A, available at http://
www.jcb.org/cgi/content/full/jcb.200401150/DC1). Inter-
estingly, ER and LG3 had nearly identical effects on MECs
(Fig. S1 B); however, no effects on the actin stress fibers of
either fibroblasts or Saos2 osteosarcoma cells grown on col-
lagen I were detected (Fig. S1 B), indicating a degree of cell
specificity. Thus, ER and LG3 induce a profound reorgani-
zation of actin cytoskeleton and focal adhesions in endothe-
lial cells derived from either large or small blood vessels.
 
ER causes colocalization of 
 
 
 
2
 
 
 
1 integrin with 
collapsed actin and supports cell attachment
 
Because ER inhibits the attachment of endothelial cells to a
collagen I substrate (Mongiat et al., 2003), we hypothesized
that ER and LG3 might exert their affects through an inte-
grin-mediated mechanism. To test this hypothesis, we first
immunostained ER- or LG3-treated HUVECs for 
 
 
 
1
 
 
 
1,
 
 
 
v
 
 
 
3, 
 
 
 
5
 
 
 
1, and 
 
 
 
2
 
 
 
1 integrins. HUVECs did not show
detectable levels of 
 
 
 
1
 
 
 
1 (Fig. 4 B), but showed significant
levels of all the other integrins tested. ER and LG3 treat-
ment resulted in a specific clustering of 
 
 
 
2
 
 
 
1 and concomi-
Figure 2. Transduction of endothelial 
cells with Ad-ER prevents capillary 
morphogenesis in collagen overlay assays. 
(A) Western immunoblotting of media 
from various cells transduced with control 
adenoviral vector (Ad-Empty) or Ad-ER 
at the designated plaque forming unit 
(pfu) using anti-ER antibody ( ER). About 
4   10
4 HUVECs and 6   10
4 MECs 
cells were transduced with indicated 
amounts of Ad-Empty or Ad-ER for 48 h. 
2   10
4 rat breast carcinoma MTLn3 
cells and 2   10
4 human colon carci-
noma WiDr cells were transduced with 
Ad-Empty or increasing amounts of 
Ad-ER as indicated. Conditioned media 
were harvested after 48 h. (B) Wells were 
precoated with 5  g/cm
2 human fibro-
nectin or laminin, or with 10.5  g/cm
2 
collagen I; 3   10
4 HUVECs were plated 
and transduced with 4.8   10
6 pfu of 
Ad-Empty or Ad-ER for 48 h. Control 
wells were left untransduced or treated 
with 150 nM ER or 50 nM LG3 for 20 
min in serum-free conditions. Collagen 
gels were added to the cells for 24 h, to 
induce capillary morphogenesis. At the 
end of the incubation, collagen gels were 
removed and cells fixed and stained. 
Bar, 100  m. 
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tant colocalization with collapsed lateral bundles of actin
(Fig. 4, G–I). In contrast, there was no colocalization with
 
 
 
v
 
 
 
3 (Fig. 4, D–F) or 
 
 
 
5
 
 
 
1 (not depicted).
Next, we determined whether or not there was any func-
tional relationship between the colocalization of 
 
 
 
2
 
 
 
1 with
collapsed actin and the activity of ER. We pretreated HU-
VECs for 10 min with saturating concentrations (10 
 
 
 
g/ml) of
a function-blocking antibody against the 
 
 
 
2
 
 
 
1 integrin, and
then added the same concentration of 
 
 
 
2
 
 
 
1 antibody supple-
mented with either ER or LG3 for an additional 10 min.
Treatment with anti-
 
 
 
2
 
 
 
1 integrin antibody resulted in com-
plete preservation of the actin stress fibers in both the ER- and
LG3-treated cells (Fig. 5, A and B). None of the other func-
tion-blocking antibodies against 
 
 
 
1
 
 
 
1 (not depicted), 
 
 
 
5
 
 
 
1,
and 
 
 
 
v
 
 
 
3 integrins prevented ER or LG3 effects (Fig. 5 A).
Next, we determined if ER itself could support endothe-
lial cell attachment and spreading, and if this attachment
and spreading could be inhibited by 
 
 
 
2
 
 
 
1 integrin-blocking
antibody. Cells readily attached and spread on the collagen
substrate, but this process could be completely (
 
 
 
98%)
blocked with 
 
 
 
2
 
 
 
1 antibody (Fig. 5 C). HUVECs also
readily attached to ER but appeared to be less spread as com-
pared with collagen I, i.e., they showed fewer and shorter
processes per cell (Fig. 5 C). HUVEC attachment to ER-
coated dishes was similarly blocked by 
 
 
 
2
 
 
 
1 antibody, but
not by 
 
 
 
1
 
 
 
1, 
 
 
 
5
 
 
 
1, or 
 
 
 
v
 
 
 
3 antibodies (unpublished data).
Collectively, these results suggest that 
 
 
 
2
 
 
 
1 integrin serves
as a functional receptor for ER.
 
ER binds to 
 
 
 
2
 
 
 
1 integrin-expressing cells and to the I 
domain of the 
 
 2 integrin subunit
We fused the coding region of ER to the heat stable human
placental alkaline phosphatase (AP), a soluble marker that
can be readily detected. Proper folding of ER/AP chimera
was tested by measuring enzyme activity in the conditioned
medium of 293-EBNA–secreting cells (unpublished data)
and by testing various dilutions of it on HUVECs. The ER/
AP-containing medium at 1:5 dilution (equivalent to  200
nM) disrupted the HUVEC actin cytoskeleton within 10
min (Fig. 6 A) in a manner identical to the purified recom-
binant protein. The activity was due to the ER moiety inso-
far as its biological function was abrogated by heat denatur-
ation (65 C for 45 min) under conditions in which the
human AP moiety is fully preserved (Mongiat et al., 2003).
Figure 3. ER and its components cause 
disassembly of HUVEC actin stress 
fibers and focal adhesions. HUVECs 
were treated with the various recombinant 
proteins (25–150 nM) for 10 min as 
indicated, fixed, permeabilized with 
0.1% Triton X-100, and stained to visualize 
actin stress fibers with rhodamine-
phalloidin, focal adhesions with anti-
vinculin mAb and appropriate FITC-
conjugated secondary antibody, and 
counterstained with DAPI. In recovery 
experiments, after the 10-min exposure, 
ER was removed and the cells were 
incubated for an additional 3 h in 
serum-free media. Bar, 10  m.Mechanism of action of endorepellin | Bix et al. 101
Next, we tested ER/AP for binding to normal murine
mammary gland epithelial cells (NMuMg) that were previ-
ously selected for the presence or absence of the  2 inte-
grin subunit (Zutter et al., 1999). The  2
  cells showed
no detectable  2 subunit (Fig. 6 B) and did not bind to
collagen I (Zutter et al., 1999). Notably, ER/AP bound
only to the  2
  cells in a dose-dependent and saturable
fashion (Fig. 6, C and D). Scatchard analysis revealed a
single receptor population with a KD of 23 nM. Binding of
ER/AP to the NMuMg  2
  cells did not cause disruption
of the actin cytoskeleton, indicating that ER might be spe-
cific for endothelial cells.
Having established a functional connection between ER
and  2 1 integrin, we determined if ER and LG3 could
physically interact with the  2I integrin domain, the major
binding site for collagen I (Emsley et al., 2000). Using sur-
face plasmon resonance spectroscopy (SPR), we found a spe-
cific binding of ER and LG3 to immobilized  2I domain
(Fig. 6, F and G). Calculation of the kinetics of binding over
a range of protein concentrations showed that ER had an af-
finity for  2I domain significantly higher than LG3 (KD of
80 nM vs. 1  M, respectively). Binding specificity was de-
termined by using two triple-helical collagen III peptides:
one of 2.9 kD containing the  2I recognition sequence
Figure 4. ER causes clustering and colocalization 
of  2 1 integrin with collapsed actin. HUVECs 
were treated with 150 nM ER for 10 min followed 
by labeling of actin (A, D, and G) or immunostaining 
with antibodies against  1 1,  v 3, or  2 1 integrin 
(B, E, and H). Identical fields were then merged 
(C, F, and I). Notice the colocalization of collapsed 
actin stress fibers with  2 1 epitopes (G–I, arrow-
heads). Lower ER concentrations (50–100 nM) 
yielded similar results (not depicted). Bar, 10  m.
Figure 5. ER supports cell attachment 
that is inhibited by  2 1 integrin block-
ing antibody. (A) ER action is blocked by 
function blocking antibody against  2 1 
integrin, but not by antibodies against 
other integrins. The cells were processed 
as in the legend to Fig. 3, after 10-min 
incubation with saturating concentrations 
(10  g/ml) of specific mAbs   ER. Bar, 
10  m. (B) Mean number of visible actin 
stress fibers per cell was calculated for 
100 randomly selected cells for each 
treatment as indicated. Error bars repre-
sent SEM. (C) Light micrographs of 
HUVECs attached to either collagen I or ER 
substrata in the presence or absence of 
anti- 2 1 integrin antibodies. Bar, 50  m.102 The Journal of Cell Biology | Volume 166, Number 1, 2004
GER (Emsley et al., 2000; Knight et al., 2000; Xu et al.,
2000) and a negative peptide consisting of (GPO)11 (where
O   hydroxyproline) of 2.94 kD. As expected, collagen III-
GER showed a dose-dependent binding to the  2I domain,
whereas (GPO)11 showed no binding at all concentrations
tested (Fig. S1 C). Moreover, solid phase binding assays us-
ing  2I-GST and GST fusion proteins as the bound sub-
strate and ER or LG3 as the soluble ligands showed a spe-
cific and high-affinity binding to immobilized  2I-GST,
with greater affinity for ER as compared with LG3, thus
corroborating the results obtained with SPR (unpublished
data). Moreover, actin collapse was blocked only by preincu-
bating ER with soluble  2I-GST but not with  1I-GST or
GST alone (Fig. 6 H). Together, these results suggest that
the  2 integrin is a major surface receptor for ER and LG3.
ER and LG3 effects on endothelial cells do not require 
cell surface heparan sulfate proteoglycans
Because endostatin requires cell surface heparan sulfate for its
biological activity (Sasaki et al., 1999), we tested if this might
also be true for ER. To this end, cells were pretreated with ei-
ther chlorate (5 or 10 mM for 2 h) or heparinase III (5 mU/
ml, for 30 min) to block the endogenous sulfation of heparan
sulfate or to degrade cell surface heparan sulfate, respectively,
followed by treatment with ER, LG3, or recombinant human
endostatin. Pretreatment with either compound failed to
block ER- or LG3-induced stress fiber collapse but did pre-
vent endostatin-induced stress fiber collapse (Fig. 7 A). Inde-
pendence from cell surface heparan sulfate for ER effects was
corroborated by experiments using heparin affinity chroma-
tography. Both ER and LG3 failed to bind to an analytical
heparin-agarose column because 72 and 78%, respectively,
eluted with  0.2 M NaCl, whereas  85% endostatin eluted
at higher NaCl concentrations (Fig. 7 B).
ER and LG3 increase [cAMP]i levels and activate PKA
Collagen I induces capillary morphogenesis through  2 1
integrin-dependent suppression of [cAMP]i and PKA activ-
ity (Whelan and Senger, 2003). Because ER’s effects mir-
rored those of collagen I, we determined if ER- and LG3-
induced actin depolymerization could involve an increase in
[cAMP]i and PKA activity, and if these changes might be
mediated by  2 1 integrin. Both ER and LG3 caused a
rapid (within 5 min) and statistically significant increase
in [cAMP]i (P   0.001) as compared with control (Fig. 8
A, 10 min treatment shown), and this increase could be
blocked by  2 1 antibody. Notably, [cAMP]i was also in-
creased in fibroblasts (Fig. S1 D), although no changes in ac-
Figure 6. ER binding and activity require the  2 1 integrin. (A) Effects of ER/AP chimera on endothelial cell stress fibers. HUVECs were 
incubated for 10 min with medium containing  200 nM ER/AP, before and after heat denaturation (65 C, for 45 min). Bar, 10  m. (B) Western 
immunoblotting of total cell lysates from NMuMg lacking or expressing the  2 integrin subunit, as indicated. (C) Dose-dependent binding 
of ER/AP-containing media to the  2
  cells. Cells were incubated for 1 h at 25 C with ER/AP media at the indicated dilutions (equivalent to 
200, 100, 50, and 25 nM ER/AP), washed and processed for AP chemiluminescence and exposure to an X-ray film. (D) Saturation binding 
curves using an experimental strategy as in C, with the exception that the values were obtained by measuring the relative light units of total 
bound ER/AP and by normalizing the results on a standard curve generated with recombinant placental AP. Values represent the mean   SEM 
(n   3). (E) Scatchard analysis shows one single class of surface receptors with relative high affinity (KD   23   2 nM). (F and G) Analyses of 
ER and LG3 binding to the I domain of  2 integrin by SPR. About 3,000 response units (RU) of  2I domain were immobilized on a CM5 chip, 
and increasing concentrations (0.1–2.0  M, from bottom to top line) of ER or LG3 were tested as indicated in a buffer containing 1 mM MgCl2. 
The profiles were corrected for response over a reference flow cell containing no immobilized protein. (H) Recombinant  2I but not  1I 
integrin domain or GST protein, blocks ER effects on HUVECs. Recombinant ER was incubated with  2I-GST or  1I-GST integrin domains or 
GST alone (at  1:8 molar ratio, respectively) for 18 h at 4 C, and then tested on HUVECs as described in Fig. 3. Bar, 10  m.Mechanism of action of endorepellin | Bix et al. 103
tin cytoskeleton were observed (Fig. S1 B), but did not ap-
preciably change in Saos2 osteosarcoma cells (Fig. S1 D),
which lack  2 1 integrin (Ivaska et al., 1999).
Next, we discovered that the fraction of active PKA was
rapidly (within 5 min) and significantly (P   0.001) in-
creased in cells exposed to ER (Fig. 8 B) or LG3 (not de-
Figure 7. ER and LG3 effects are independent of cell surface heparan sulfate. (A) HUVECs were pretreated with either chlorate (5 or 10 mM 
for 2 h) or heparinase III (E.C.4.2.2.8.; 5 mU/ml, for 30 min) and then exposed to equimolar amounts (50 or 150 nM) of ER, LG3, or human 
endostatin. Actin fibers were visualized as described in legend to Fig. 3. Bar, 10  m. (B) ER and LG3 do not bind to an analytical heparin-
agarose column. The majority of ER or LG3 (72% and 78%, respectively) elutes at NaCl   0.2 M, in contrast to Endostatin,  85% of which 
elutes at higher NaCl molarities.
Figure 8. ER and LG3 increase [cAMP]i, 
activate PKA, and require calcium for activity. 
(A) HUVECs were treated with ER or LG3   
 2 1 blocking antibody (10  g/ml) for 10 min. 
Total cAMP levels were measured with an 
enzyme-linked immunoassay kit. Results are 
plotted as percentage of control OD405 arbi-
trarily set to 100%. (B) The percentage of active 
PKA is significantly enhanced (P   0.001) at 
5 min and sustained for at least 20 min by ER, 
as measured with an ELISA based assay. (C) 
HUVECs were pretreated with the two cell 
permeable PKA inhibitors, KT-5720 (10  M) 
or PKI14-22 (0.41  M) for 30 min, and then ex-
posed to ER and LG3 for an additional 10 min 
using the same concentrations of PKA inhibitors. 
The mean number of visible actin stress fibers 
per cell was calculated for 100 randomly selected 
cells for each condition. Error bars represent 
SEM. (D) Effects of low Ca
2  on ER and LG3 
activity. HUVECs were first exposed to normal 
(1.8 mM) or half-normal (0.9 mM) Ca
2  con-
centrations for 20 min, and then to ER or LG3 
for 10 min, followed by staining for actin.104 The Journal of Cell Biology | Volume 166, Number 1, 2004
picted). PKA activity remained elevated for up to 20 min.
The ER-induced activation of PKA was further confirmed
by experiments in which HUVECs were preincubated for
30 min with one of two cell-permeable inhibitors specific for
PKA, KT-5720, or PKI14-22 followed by ER or LG3 treat-
ment. Both PKA inhibitors blocked ER- and LG3-induced
actin collapse (Fig. 8 C), indicating that PKA is required for
ER action.
Because integrin-mediated signaling is known to be cation
dependent (Giancotti and Ruoslahti, 1999), and because ER
has putative Ca
2  binding sites within its LG domains, we
determined if ER and LG3 effects could also be Ca
2  depen-
dent. As the complete chelating of these ions with EDTA is
readily toxic to cells, we instead exposed the HUVECs to
media with either 0.9 or 0.45 mM Ca
2  (50 and 25% of the
normal Ca
2  concentration, respectively). Extracellular Ca
2 
reduction completely blocked the effects of ER and LG3 on
actin stress fibers (Fig. 8 D, 0.45 mM Ca
2  not depicted).
Collectively, these results establish that ER induces
cAMP-dependent PKA activity in conjunction with eleva-
tion of [cAMP]i, and that PKA activity and Ca
2  are re-
quired for downstream signaling.
ER activates FAK, and transiently p38 MAPK
and Hsp27
Integrin engagement affects the activity of the small
GTPases RhoA, Rac1, and Cdc42 (Kjoller and Hall, 1999).
These proteins function as key regulators of distinct signal-
ing pathways and affect the microfilament organization of
most cells. RhoA affects actin stress fibers, whereas Rac1 and
Cdc42 influence lamellipodia and filipodia formation, re-
spectively (Kjoller and Hall, 1999). Because endostatin sup-
presses RhoA activity via  5 1 integrin-mediated activation
of Src tyrosine kinase/p190RhoGAP (Wickström et al.,
2003), we first tested the potent Src kinase inhibitor PP1
(Hanke et al., 1996). We found no effects on ER or LG3 ac-
tivity (Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200401150/DC1), suggesting that ER engagement
with the  2 1 integrin does not activate this signaling path-
way. Next, we tested the levels of active RhoA and Rac1 us-
ing affinity precipitation with Rhotekin Rho-binding do-
main-agarose or PAK-1 p21-binding domain-agarose (Ren
et al., 1999). We did not find any appreciable changes in-
duced by ER or LG3 in either case (Fig. 9 A). Lack of in-
volvement of the Rho pathway was further demonstrated by
Figure 9. ER activates FAK and p38 MAPK. 
(A) Affinity precipitation of RhoA-GTP 
and Rac1-GTP in HUVECs after a 30-min 
incubation with PBS, ER, or LG3. The 
cell lysates were then incubated with 
Rhotekin Rho binding domain-agarose 
or PAK-1 p21-binding domain-agarose. 
The bound proteins were eluted with 
Laemmli buffer and detected by immuno-
blotting using mAbs against RhoA or 
Rac1. Notice that in the RhoA lysate, 
only 20% of total cell extract was loaded. 
(B) Detection of Erk1/Erk2 MAPK phos-
phorylated at T202 and Y204 (P-Erk1/
Erk2) and total Erk1/Erk2 MAPK upon 
stimulation of serum starved HUVECs 
with 10% FCS, ER (100 nM), endostatin 
(100 nM), ER and endostatin (100 nM 
each), FGF2 (75 ng/ml)   heparin (100 
ng/ml), VEGF (75 ng/ml), or EGF (75 ng/
ml), as indicated. (C) Dose response 
effects of ER and LG3 on FAK(Y397) and 
total FAK in HUVECs at 1 h. (D) Quanti-
zation of the dose response effects of 
ER and LG3 on activated FAK at 1 h. 
(E) Time course response of activated 
FAK after ER treatment (mean   SEM, 
n   5) in the absence ( ) or presence ( ) 
of 1  g/ml
 geldanamycin. (F) Time course 
changes in p38 MAPK phosphorylated at 
T180 and Y182 (P-p38) and total p38 in 
response to ER treatment. (G) Quantiza-
tion of the dose response effects of ER on 
activated p38 MAPK.Mechanism of action of endorepellin | Bix et al. 105
the failure of Y27632, a specific inhibitor of the Rho effector
ROCK (Uehata et al., 1997), to block ER or LG3 activity
(Fig. S2).
As a readout of ER activity, we investigated the status of
extracellular signal-regulated protein kinase 1,2 (Erk1/2)
known to be activated by various integrins as well as by
cross-talk between integrins and other surface receptors (Gi-
ancotti and Ruoslahti, 1999). As positive controls we used
bovine serum, FGF2 with or without heparin, VEGF, and
EGF, which are all known to activate this signaling pathway.
We found that neither ER nor endostatin activated this
pathway, whereas all the positive controls did (Fig. 9 B).
In initial experiments, we noticed a 125-kD protein,
which was rapidly phosphorylated by ER as well as by
VEGF and FGF2 (unpublished data), suggesting to us
that p125 FAK might be involved in ER signaling. We
found a prominent activation of FAK at one of its major
phosphorylation sites (Y397), which was maximal at 40–
60 nM for both ER and LG3 (Fig. 9, C and D). Time
course experiments showed a progressive activation of
FAK, which was maximal at 40 min (Fig. 9 E) and contin-
ued at similar levels for 60 min (note that the dose–
response experiments lasted 1 h; Fig. 9, C and D). The
requirement for FAK was further corroborated by experi-
ments in which 1-h preincubation with 1  g/ml geldana-
mycin, an antibiotic that blocks FAK phosphorylation in
HUVECs (Rousseau et al., 2000), totally blocked ER or
LG3 activity on actin stress fibers (Fig. S2), as well as FAK
phosphorylation (Fig. 9 E).
Because  2 1 integrin activation is associated with activa-
tion of p38 MAPK in other cell types (Ivaska et al., 1999;
Klekokta et al., 2001), we tested whether or not p38 MAPK
was affected by ER in HUVECs. Indeed, p38 MAPK was
transiently activated by ER (Fig. 9 F), with a peak at 5 min
and a progressive decline thereafter (Fig. 9 G). In several ex-
periments, total p38 was markedly reduced at 40 min (Fig. 9
F), suggesting that p38 might be targeted for degradation.
The requirement for p38 MAPK was further demonstrated
by the complete block of ER- and LG3-mediated actin col-
lapse by a 1-h pretreatment with SB202190 (5  g/ml; Fig.
S2), which blocks the p38-mediated activation of ATF-2
(Jiang et al., 1996). Moreover, ER effects were totally
blocked by SB203580 (unpublished data), which blocks the
phosphorylation of Hsp27, a well established downstream
effector of p38 MAPK (Guay et al., 1997). Therefore, we
tested whether or not the phosphorylation status of Hsp27
followed the transient phosphorylation of p38 MAPK. We
found that Hsp27 was rapidly phosphorylated at Ser15 by
ER treatment and that its activation peaked at 10 min (Fig.
S3, A and B, available at http://www.jcb.org/cgi/content/
full/jcb.200401150/DC1), as also visualized by immuno-
staining using the same anti–P-Hsp27 (Fig. S3 C). Notably,
the total protein content of Hsp27 was also significantly re-
duced at 40 min, suggesting that both p38 MAPK and
Hsp27 might be destined for degradation.
Thus, we conclude that ER and LG3 cause a sustained
phosphorylation of FAK and a transient activation of
p38 MAPK and Hsp27, both of which are subsequently
down-regulated.
Discussion
Having generated recombinant ER and two deletion frag-
ments encompassing the two LG (LG1/LG2) and the termi-
nal (LG3) module, we investigated their antiangiogenic
properties using a coculture system within Matrigel. Al-
though the ER-secreting cells were allowed to grow within a
three-dimensional matrix, the endothelial cells were seeded
on the top and cocultured for another 24 h, during which
time they did not have any direct physical contact with the
293-EBNA cells, and any effects on tube formation would
be due to secreted factors. The results showed a complete ab-
rogation of capillary morphogenesis induced by ER or LG3,
but not by LG1/LG2, indicating that most of the biological
activity of ER resides within its terminal globular domain.
These findings were further corroborated by using recombi-
nant proteins in both Matrigel and collagen I gel overlay as-
says. It is notable that we used serum and both FGF2 and
VEGF (Mongiat et al., 2003). Thus, ER is capable of over-
coming the powerful angiogenic properties of Matrigel, col-
lagen I, and VEGF/FGF2.
We further determined if the endogenous secretion of ER
by endothelial cells via Ad-ER would disrupt capillary mor-
phogenesis on different substrata in a dominant-negative
fashion because endothelial cells synthesize perlecan. Al-
though the control cells formed tubes, Ad-ER transduced
HUVECs and MECs failed to do so. Thus, inhibition of cap-
illary morphogenesis can be reproduced by the endogenous
synthesis of ER as well as the addition of exogenous recombi-
nant protein, and these effects occur in endothelial cells de-
rived from umbilical vein or dermal microvasculature.
Reorganization of actin filaments, controlled by actin po-
lymerization–depolymerization events, is essential in adapt-
ing the cell shape and its motility to the surrounding mi-
croenvironment (Burridge et al., 1997). This process plays a
central role in endothelial cell migration and capillary mor-
phogenesis. In this study, we discovered that ER and LG3
exert a profound effect on cytoskeletal dynamics by disrupt-
ing actin filaments and focal adhesions within 10 min, in a
Ca
2 -dependent but heparan sulfate–independent fashion.
Ca
2  dependence is likely due to Ca
2  binding sites found
within ER/LG3. The LG1/LG2 construct did not show any
significant activity. Furthermore, we were able to inhibit ER
activity by first incubating with antibodies against LG3 (un-
published data), which underscores LG3 s importance in
mediating ER activity. Notably, perlecan LG2 module is the
major binding site for collagen XVIII/endostatin (Mongiat
et al., 2003) and LG1/LG2 modules are required for high af-
finity binding to  -dystroglycan, whereas LG3 by itself has
much lower affinity (Talts et al., 1999). These data suggest
that LG3 is relatively free of high affinity interactions within
basement membranes, thereby allowing proteolytic cleavage
to occur during the early stages of angiogenesis.
Collagen I regulates endothelial alignment into cords by a
specific interaction with  1 1 and  2 1 integrins (Senger et
al., 2002). Although microvascular endothelial cells require
blocking antibodies to both integrins to abrogate capillary
morphogenesis (Whelan and Senger, 2003), HUVECs re-
quire only anti- 2 1 blocking antibody for the full effect
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LG3 treatment caused a specific clustering of  2 1 and con-
comitant colocalization with collapsed lateral bundles of ac-
tin. In contrast, there was no colocalization with  v 3 or
 5 1 integrins. Next, we established a functional relation-
ship between the colocalization of  2 1 with collapsed actin
and the activity of ER by showing that a function-blocking
antibody against the  2 1 integrin (but not toward  1 1,
 v 3, or  5 1 integrins) could counteract the ER- and
LG3-mediated effects on both HUVECs and MECs. We
further discovered that the presence of  2 1 was essential for
proper ER binding, as measured by the fully functional ER/
AP chimeric protein. Notably, both the NMuMg  2
  and
 2
  express intermediate to high levels of  5,  6,  1, and
 4 integrin subunits, whereas all lack the  1 subunit (Zutter
et al., 1999), further strengthening the concept that ER re-
quires the  2 integrin subunit for its cell surface binding. In
agreement with these findings, we discovered that ER and
LG3 bound to the  2 I integrin domain, the major binding
site for collagen I (Emsley et al., 2000; Knight et al., 2000;
Xu et al., 2000), and that ER activity could be counteracted
by soluble  2I-GST but not by  1I-GST or GST alone. In-
terestingly, ER had higher affinity for  2 I domain than
LG3, suggesting that LG1/LG2 and/or EGF-like motifs
might be important secondary binding sites for the integrin.
Collagen I suppresses [cAMP]i in vascular smooth muscle
(Wang et al., 1999) and microvascular endothelial (Whelan
and Senger, 2003) cells; and the attachment of endothelial
cells to various extracellular matrix constituents, including
collagen I, fibronectin, and vitronectin, suppresses PKA ac-
tivity (Kim et al., 2000). PKA typically becomes activated
upon binding to cAMP, and thus agents that elevate
[cAMP]i such as forskolin, dibutyryl cAMP, or isoproterenol
can all activate PKA (Schoenwaelder and Burridge, 1999).
Pharmacological elevation of [cAMP]i causes rapid and tran-
sient morphological changes that lead to a “cAMP pheno-
type;” i.e., dissolution of actin cytoskeleton and rounding up
of the cells (Dong et al., 1998). In endothelial cells, eleva-
tion of [cAMP]i blocks collagen-induced actin polymeriza-
tion and capillary morphogenesis in a way that mimics the
action of  1 1/ 2 1 integrin-blocking antibodies (Whelan
and Senger, 2003). We reasoned that ER might activate
[cAMP]i because its effects were similar to those caused by
agents that induce [cAMP]i. Both ER and LG3 caused a
rapid increase in HUVEC [cAMP]i that could be blocked by
 2 1 antibody, further supporting a role for this integrin in
ER/LG3 signaling. [cAMP]i was also increased in skin fibro-
blasts, although no changes in actin cytoskeleton were ob-
served, in agreement with previous results (Whelan and Sen-
ger, 2003); however, [cAMP]i did not appreciably change in
Saos2 cells, which lack  2 1 integrin (Ivaska et al., 1999).
We further demonstrated a requirement for PKA activity us-
ing two cell-permeable inhibitors specific for PKA, KT-
5720 and PKI14-22. Both PKA inhibitors blocked ER- and
LG3-induced actin stress fiber collapse, suggesting that both
ER and LG3 require PKA activity via [cAMP]i elevation. In-
deed, total PKA activity was significantly increased in ER- or
LG3-treated HUVECs.
Activated PKA antagonizes the activity of RhoA through
a specific phosphorylation at Ser188 (Lang et al., 1996),
which leads to a decreased affinity for its effector ROCK
(Dong et al., 1998). When HUVECs treated with ER or
LG3 were probed for changes in GTP-bound (active) RhoA
or Rac1, we found no significant involvement of these GTP-
ases in ER signaling. That the Rho pathway was not in-
volved was further shown by the lack of inhibition of ER or
LG3 activity by pretreatment of the cells with 1  M
Y27632, a specific inhibitor of ROCK (Uehata et al., 1997).
Because integrin engagement suppresses RhoA activity via a
Src-dependent mechanism (Arthur et al., 2000), we tested
the potent Src kinase inhibitor PP1 (Hanke et al., 1996),
which prevents the activity of endostatin on HUVECs
(Wickström et al., 2003). We found no PP1 effects on ER
or LG3 activity, suggesting that ER engagement with  2 1
does not activate this signaling pathway. Moreover, we
found that ER did not activate the Erk1/Erk2 signaling
pathway known to be activated by various integrins as well
as by cross-talk between integrins and other surface receptors
(Giancotti and Ruoslahti, 1999).
FAK is an important receptor-proximal link between
growth factor receptors and integrin signaling (Sieg et al.,
2000). Moreover, FAK is required for blood vessel morpho-
genesis (Ilic et al., 2003), whereas ER prevents capillary
morphogenesis. We found a protracted activation of FAK at
one of its major phosphorylation sites (Y397). This finding
is of interest because FAK phosphorylation is associated with
focal adhesion disassembly (Schoenwaelder and Burridge,
1999). In contrast, collagen I inhibits FAK-Y397 in HU-
VECs (Sweeney et al., 2003), essentially mirroring the ef-
fects of ER. Requirement for FAK activation was further
proved by the complete block of ER activity by geldanamy-
cin, an antibiotic that blocks the VEGF-induced FAK phos-
phorylation in HUVECs (Rousseau et al., 2000). A role for
FAK in the formation of actin stress fibers is further sup-
ported by the finding that this process can be completely
abolished by overexpressing FRNK, a noncatalytic COOH-
terminal portion of FAK that acts as a negative regulator
of FAK (Rousseau et al., 2000). It is noteworthy that ex-
ogenous perlecan induces FNRK in smooth muscle cells,
thereby suppressing the FAK-mediated activation of Erk1/2
growth signal (Walker et al., 2003).
ER causes a transient activation of p38 MAPK, followed
by down-regulation. In contrast, collagen I engagement of
the  2 1 integrin in HUVECs causes a sustained ( 2 h)
phosphorylation of p38 MAPK (Sweeney et al., 2003). No-
tably, the p38 inhibitor SB202190, which blocks the ability
of p38 to phosphorylate the transcription factor ATF-2
(Jiang et al., 1996), inhibits collagen-induced capillary mor-
phogenesis (Sweeney et al., 2003) and completely blocked
the action of ER and LG3. In mice lacking p38  MAPK
(Mudgett et al., 2000) and Mekk3 (Hanke et al., 1996), the
upstream activator of p38 MAPK, significant defects in
placental angiogenesis and blood vessel development were
found. These studies have shown that p38  MAPK is not
essential for vasculogenesis, the process by which angioblasts
differentiate to form primary capillaries, but rather is re-
quired for the vascular remodeling associated with angiogen-
esis. Our signaling axis is further strengthened by reports es-
tablishing a link between activation of  2 integrin subunit
and p38 MAPK (Ivaska et al., 1999; Klekokta et al., 2001).
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HUVECs, whereas inhibition of Erk1/2 is ineffective (Rous-
seau et al., 1997). Treatment of HUVECs with VEGF
causes a transient phosphorylation of p38 MAPK, reorgani-
zation of actin into long stress fibers, and vinculin assembly
(Rousseau et al., 1997). Therefore, it is possible that several
responses associated with actin filament dynamics may be
dependent on p38 activation/deactivation events.
ER causes transient activation of Hsp27, a small chaper-
one protein regulated by p38 MAPK and associated with ac-
tin dynamics (Guay et al., 1997; Huot et al., 1997). Inter-
estingly, activation of Hsp27 is usually associated with stress
fiber formation in HUVECs (Huot et al., 1997) rather than
disassembly. Indeed, HUVECs express high levels of Hsp27
as compared with fibroblasts (6 vs. 1–2 ng/mg
 1 total pro-
tein), and this might explain why endothelial cells respond
differently (stress fiber formation vs. actin fragmentation)
than fibroblasts to Hsp27 activation (Huot et al., 1997).
This apparent discrepancy with our results suggests that the
biology of Hsp27 interaction with actin fibers is more
complex than previously thought. Alternatively, it is pos-
sible that other, as yet undiscovered, pathways are activated
by ER. However, by inhibiting activation of Hsp27 with
SB203580, we were able to prevent ER-induced actin disas-
sembly, suggesting that the p38 MAPK/Hsp27 axis is pri-
marily involved. As in the case of p38 MAPK, Hsp27 pro-
tein levels subsequently declined. Thus, it is possible that the
down-regulation of p38 MAPK/Hsp27 is a distinguishing
feature of ER signaling.
In conclusion, we propose a working model (Fig. 10)
where ER mediates its antiangiogenic effects by first inter-
acting with  2 1 integrin on the endothelial cell surface, re-
sulting in a disruption of the outside-in integrin signaling
that normally provides proangiogenic cues. This ER– 2 1
interaction leads to an increase in [cAMP]i; activation of
PKA and FAK, which in turn leads to transient phosphory-
lation of p38 MAPK and Hsp27; and concomitant disas-
sembly of focal adhesions and actin stress fibers. As a result
of this reversible and Ca
2 -dependent process, ER causes en-
dothelial cells to become refractory to angiogenic cues, both
soluble cues, such as FGF2 and VEGF, and static cues, such
as collagen and fibronectin. The end result is a profound
block of endothelial cell migration and angiogenesis.
Materials and methods
Recombinant proteins and generation of antisera
Recombinant human ER (E3687-S4391), LG1-LG2 (E3687-P4107), LG3
(G4182-S4391), and endostatin were produced in 293-EBNA cells as de-
scribed previously (Mongiat et al., 2003). Recombinant  2I-GST or  1I-
GST integrin domains were purified as described previously (Dickeson et
al., 1997). Purified ER or LG3 (100  g) were mixed with complete Freund’s
adjuvant and injected into rabbits to raise specific antisera. Booster injec-
tions were performed at 4 and 8 wk after primary injection.
Preparation of adenovirus vectors and collagen overlay assays
Ad-ER, Ad-LacZ, and Ad-Empty were prepared using the AdEasy
TM Adeno-
viral Vector System (Stratagene). Human embryonic kidney 293 cells were
transduced with the Ad-vectors containing the gene of interest (ER or LacZ)
using the MBS Transfection kit (Stratagene). Cells were amplified and virus
was purified using the Virapur Purification kit (BD Biosciences). The virus
was titrated using an end point dilution assay (TCID50), and transduction
efficiency was determined by in situ staining with  -galactosidase (Strat-
agene). Cells were transduced with Ad-ER or Ad-Empty at an MOI of 80–
160 for 48 h, and then were overlaid with 100  l/cm
2 of collagen gel. After
gel solidification, conditioned media (containing Ad-ER, Ad-Empty, or no
virus) were added back to the cells.
Immunofluorescence, cell adhesion, cAMP, and PKA assays
HUVECs (passage 4–8) and MECs (Yale Skin Diseases Research Center)
were similarly cultured on collagen-coated flasks in complete media
(Mongiat et al., 2003) or EGM-2 MV media (Clonetics), respectively. Fibro-
blasts and Saos2 osteosarcoma cells were similarly cultured in DME sup-
plemented with 10% FBS (GIBCO BRL). Monoclonal blocking antibody to
integrins  2 1 (mAb 1998Z),  1 (mAb 1973Z),  v 3 (mAb 1976), or  5 1
(mAb 1969), all obtained from Chemicon, were added to the cells. In other
experiments, cells were treated with the PKA inhibitors KT5720 (10  M) or
PKI14-22 (0.41  M; Calbiochem). Cells were pretreated with 5 mU/ml hepa-
rinase III (Sigma-Aldrich) for 30 min, or either 5 mM or 10 mM chlorate for
2 h. After serum starving, the cells were treated with serum-free or cal-
cium-modified media containing test compounds as indicated. Routinely,
cells were washed with PBS, fixed with 4% PFA, permeabilized with 0.1%
Triton-X for 3 min, and incubated with PBS/5% BSA for 30 min. The cells
were immunolabeled with mAbs against vinculin (V9131; Sigma-Aldrich)
or various integrins as mentioned in this paragraph followed by the appro-
priate FITC-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories). The cells were also stained with rhodamine-phalloidin and
DAPI (Sigma-Aldrich). Images were captured with a microscope (model
DP12; Olympus) and a SPOT CCD camera and processed with Adobe
Photoshop 7.0. Actin stress fibers were assessed from 100 randomly se-
lected cells.
For cell adhesion, 96-well dishes were coated overnight at 4 C with ER
(40  g/ml), collagen I (100  g/ml), or 1% BSA. After blocking with 1%
BSA for 30 min, HUVECs were trypsinized, resuspended in serum-free
M199 media, and allowed to recover in suspension for 20 min at 37 C.
The cells were incubated   anti- 2 1 blocking antibody (10  g/ml) for 20
min at 37 C, and then plated for 3 h. The wells were rinsed with PBS, fixed
Figure 10. Schematic model representing the regulation of actin 
stress fibers and focal adhesions by ER. The model shows activation 
of a signaling cascade that involves ER interaction with  2 1, acti-
vation of cAMP, PKA, and FAK, followed by the transient activation 
of p38 MAPK and Hsp27, and ultimately disassembly of actin stress 
fibers and focal adhesions. The various blocking agents are also 
illustrated. For additional details see the text.108 The Journal of Cell Biology | Volume 166, Number 1, 2004
with 4% PFA, stained with 0.1% crystal violet, solubilized with acetic acid
(10% wt/vol), and OD560 was measured to quantify the adherent cells.
[cAMP]i and PKA activity were measured with an enzyme-linked immu-
noassay kit (Biotechnologies) and a protein kinase assay kit (Calbiochem),
respectively.
ER/AP, heparin binding, BIAcore studies, and determination of 
active RhoA and Rac1
NMuMG, selected for the presence or absence of the  2 integrin subunit,
were cultured as described previously (Zutter et al., 1999). ER/AP binding
assays were performed as described previously (Mongiat et al., 2003). To
assess  2 integrin expression, total cell lysates were immunoblotted with
anti- 2 integrin (AB1936; Chemicon) and anti-GAPDH (Immunochemical)
antibodies. For heparin binding, recombinant proteins ( 10  g each) were
analyzed on an analytical heparin-agarose column (Sigma-Aldrich) and
eluted with increasing concentrations (0.1–1.2 M) of NaCl in 50 mM Tris-
HCl, pH 7.5, 0.05% BSA, and 0.01% NaN3. SPR studies were performed on
immobilized  2I domain using BIAcore 3000 system and evaluated with
the BIAevaluation software (Xu et al., 2000). For determination of active
RhoA and Rac1, cells were lysed in Mg
2  buffer (MLB; Upstate Biotechnol-
ogy) containing 25 mM NaF, 1 mM Na3VO4, and protease inhibitor
(Roche). The lysates were incubated with Rhotekin Rho binding domain-
agarose or PAK-1 p21-binding domain-agarose (Upstate Biotechnology) at
4 C for 60 min, washed three times with MLB buffer, solubilized, and
detected by immunoblotting using mAbs against RhoA (Santa Cruz Bio-
technology, Inc.) or Rac1 (BD Biosciences). Antibodies against Erk1/2
(Promega), P-Erk1/2 (Cell Signaling), FAK (BD Biosciences), P-FAK(Y397)
(Upstate Biotechnology), p38 and P-p38 (Cell Signaling), total Hsp27 and
P-Hsp27 (Santa Cruz Biotechnology, Inc.) were also used in immunoblottings.
Online supplemental material
Fig. S1 indicates the quantification of ER and LG3 effects on HUVEC actin
stress fibers, demonstrates the specificity of ER and LG3 actin effects for
endothelial cells (vs. fibroblasts and Saos2 cells), demonstrates that ER
causes a significant increase in [cAMP]i in MECs and fibroblasts (cells that
possess the  2 1 integrin) but not in Saos2 cells, which lack this integrin,
and demonstrates positive control (triple helical collagen III peptide) and
negative control ((GPO)11) interactions with  2I integrin domain by SPR.
Fig. S2 demonstrates that geldanamycin (a FAK inhibitor) and SB202190
(a p38MAPK inhibitor), but not PP1 (a Src inhibitor) or Y27632 (a ROCK
inhibitor), block ER and LG3 actin stress fiber collapse as compared with
controls.
Fig. S3 indicates that ER causes a transient phosphorylation of Hsp27
maximal after 10 min, followed by a gradual decrease in total Hsp27.
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200401150/DC1.
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